Table 3.
Laboratory data for 124 patients with type 2 diabetes according to progression of diabetic nephropathy
| Stage 1 | Stage 2 | Stage 3 | Stage 4 | P value | |
|---|---|---|---|---|---|
| Subjects (male/female) |
59(42/17) |
40(24/16) |
19(17/2) |
6(5/1) |
|
| Serum creatinine (mg/dl) |
0.73±0.02 |
0.81±0.03 |
0.87±0.03* |
1.2±0.10**,##,$$ |
< 0.001 |
| eGFR (ml/min) |
80.1±2.6 |
69.3±2.9* |
68.7±4.0 |
46.5±3.2**,# |
<0.001 |
| Albuminuria (mg/g creatinine) |
12.4±1.1 |
95.0±10.7** |
483.8±63.6**,## |
538.0±98.4**,## |
<0.001 |
| Serum osteoprotegerin (pg/ml) |
183.8±117.5 |
329.6±227.4 |
168.1±87.2 |
59.8±27.6 |
0.876 |
| Serum osteocalcin (ng/ml) |
1.58±0.21 |
1.79±0.26 |
1.35 ±0.32 |
2.06 ±0.76 |
0.696 |
| Serum 25-hydroxyvitamin D3 (nmol/l) |
85.3±5.71 |
86.2±6.52 |
103.3±14.9 |
81.1±18.8 |
0.516 |
| Serum FGF23 (pg/ml) |
32.6±1.83 |
33.2±3.53 |
36.1±3.57 |
58.7±7.08** |
0.007 |
| No calcification, n |
41 |
26 |
13 |
5 |
|
| Calcification, n | 18 | 14 | 4 | 1 |
Values are shown as mean ± SE and were analyzed by ANOVA. * P < 0.05 vs. 1st quartile. ** P < 0.01 vs. 1st quartile. # P < 0.05 vs. 2nd quartile. ## P < 0.01 vs. 2nd quartile. $ P < 0.05 vs. 3rd quartile. $$ P < 0.01 vs. 3rd quartile.